Rationale, Design, and Participant Baseline Characteristics of a Parallel Randomized Trial of the Effect of Replacing SSBs with Cow’s Milk Versus Soymilk on Intrahepatocellular Lipid and Other Cardiometabolic Risk Factors in Adults with Obesity Who Consume Sugar-Sweetened Beverages: The Soy Treatment Evaluation for Metabolic health (STEM) Trial
Nutrients · 24.03.2026 · 18 (7) · 1026
DOI: 10.3390/nu18071026 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 24.03.2026. Verfasst von Madeline N Erlich und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada. Hauptthemen laut MEDLINE: Soy Milk, Obesity, Cardiometabolic Risk Factors, Milk. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United Soybean Board (the United States Department of Agriculture [USDA] "Soy Check-off Program"), Dairy Farmers of Canada, Nutrition Trialists Network Fund.
Abstract (Originalsprache)
Background/Objectives: Liver fat represents an early metabolic lesion in the development of diabetes and its cardiometabolic complications. Diets high in free sugars, particularly from sugar-sweetened beverages (SSBs), are associated with abdominal obesity and increased cardiometabolic risk, prompting global guidelines to limit SSBs as a major public health strategy. Low-fat cow’s milk is promoted as the preferred caloric replacement strategy for SSBs due to its high nutritional value and cardiometabolic advantages. Fortified soymilk is a plant-based alternative with approved health claims for cholesterol and coronary heart disease risk reduction that offers an equivalent nutritional value to cow’s milk. However, given concerns about its classification as an ultra-processed food (UPF), it is unclear whether soymilk offers comparable metabolic health benefits to milk as part of clinical and public health strategies to reduce SSB intake. The Soy Treatment Evaluation for Metabolic (STEM) health trial seeks to evaluate the impact of replacing SSBs with either 2% soymilk or 2% cow’s milk on liver fat and other cardiometabolic risk factors in habitual adult consumers of SSBs with obesity.
Methods
The STEM trial is a 24-week, pragmatic, 3-arm, parallel, randomized trial. We recruited adults with obesity (high BMI plus high waist circumference based on ethnic specific cut-offs) consuming ≥1 SSB/day. Participants were randomized to one of three groups based on their usual SSB intake at baseline (servings/day): continued SSB (355 mL can) intake; replacement with fortified, sweetened 2% soymilk (250 mL); or replacement with 2% cow’s milk (250 mL). The primary outcome is the change in intrahepatocellular lipid (IHCL) measured by 1H-MRS at 24 weeks. Hierarchical testing will be done to reduce the familywise error rate. The superiority of cow’s milk to SSBs will be assessed first to establish assay sensitivity. If superiority is established, then the non-inferiority of soymilk to cow’s milk will be assessed using a pre-specified non-inferiority margin of 1.5% IHCL units (assessed by difference of means using a 90% confidence interval [CI]). Analyses will be conducted according to the intention-to-treat (ITT) principle using inverse probability weighting (IPW) for superiority testing and per-protocol analyses for non-inferiority testing, using ANCOVA adjusted for age, sex, metabolic dysfunction-associated steatotic liver disease (MASLD) status, medication use, intervention dose, and baseline levels. We hypothesize that soymilk will be non-inferior to cow’s milk (Clinicaltrials.gov NCT05191160).
Results
Recruitment began in November 2021. A total of 3050 individuals were screened. We randomized 186 participants (62 per group) between 19 April 2022 and 16 April 2024. Participants are 57% male; with a mean [SD] age of 39.9 [11.8] years; BMI of 34.6 [6.1] kg/m2, waist circumference of 112.6 [13.8] cm; IHCL of 10.0 [8.2] % with 64.1% meeting the criteria for MASLD; and SSBs intake of 2.3 [1.3] servings/day.
Conclusions
Baseline characteristics were balanced across the study arms, with participants representing adults with a high-risk metabolic phenotype, and 64.1% meeting the criteria for MASLD. Findings will contribute to evidence on the cardiometabolic benefits of soymilk, informing clinical practice guidelines and public health policy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
- Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, Toronto, ON M5B 1W8, Canada.
- Department of Family Relations and Applied Nutrition, University of Guelph, Guelph, ON N1G 2W1, Canada.
- Clinical Nutrition Department, Civic Campus, The Ottawa Hospital, Ottawa, ON K1Y 4E9, Canada.
- Division of Cardiac Prevention and Rehabilitation, University of Ottawa Heart Institute, Ottawa, ON K1Y 4W7, Canada.
- College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
ORCID-Profile: Diana Ghidanac, Sonia Blanco Mejia, Sabrina Ayoub-Charette, Tauseef A Khan, D Dan Ramdath, Lawrence A Leiter, David J A Jenkins, John L Sievenpiper
Förderung
- United Soybean Board (the United States Department of Agriculture [USDA] "Soy Check-off Program")
- Dairy Farmers of Canada
- Nutrition Trialists Network Fund
- Plant Milk Fund
- The Canada Foundation for Innovation (CFI) and the Ministry of Research and Innovation’s Ontario Research Fund
- CIHR Canadian Graduate Scholarship Doctoral Award
- Toronto 3D PhD Scholarship
- Undergraduate Summer Research Opportunity Program
Zitieren
APA
Erlich, M. N., Ghidanac, D., Blanco Mejia, S., Ayoub-Charette, S., Vittes Combe, C., Khan, T. A., Ramdath, D., Crewson, H., Beck, A., Silva, C., Ramdath, D. D., Metherel, A. H., Leiter, L. A., Bazinet, R. P., Kendall, C. W. C., Jenkins, D. J. A., Chiavaroli, L., & Sievenpiper, J. L. (2026). Rationale, Design, and Participant Baseline Characteristics of a Parallel Randomized Trial of the Effect of Replacing SSBs with Cow’s Milk Versus Soymilk on Intrahepatocellular Lipid and Other Cardiometabolic Risk Factors in Adults with Obesity Who Consume Sugar-Sweetened Beverages: The Soy Treatment Evaluation for Metabolic health (STEM) Trial. Nutrients, 18(7), 1026. https://doi.org/10.3390/nu18071026
Vancouver
Erlich MN, Ghidanac D, Blanco Mejia S, Ayoub-Charette S, Vittes Combe C, Khan TA, et al. Rationale, Design, and Participant Baseline Characteristics of a Parallel Randomized Trial of the Effect of Replacing SSBs with Cow’s Milk Versus Soymilk on Intrahepatocellular Lipid and Other Cardiometabolic Risk Factors in Adults with Obesity Who Consume Sugar-Sweetened Beverages: The Soy Treatment Evaluation for Metabolic health (STEM) Trial. Nutrients. 2026;18(7):1026. doi:10.3390/nu18071026
BibTeX
@article{Erlich2026,
author = {Erlich, Madeline N and Ghidanac, Diana and Blanco Mejia, Sonia and Ayoub-Charette, Sabrina and Vittes Combe, Claudia and Khan, Tauseef A and Ramdath, Devina and Crewson, Heather and Beck, Amanda and Silva, Constança and Ramdath, D Dan and Metherel, Adam H and Leiter, Lawrence A and Bazinet, Richard P and Kendall, Cyril W C and Jenkins, David J A and Chiavaroli, Laura and Sievenpiper, John L},
title = {Rationale, Design, and Participant Baseline Characteristics of a Parallel Randomized Trial of the Effect of Replacing SSBs with Cow’s Milk Versus Soymilk on Intrahepatocellular Lipid and Other Cardiometabolic Risk Factors in Adults with Obesity Who Consume Sugar-Sweetened Beverages: The Soy Treatment Evaluation for Metabolic health (STEM) Trial},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {7},
pages = {1026},
doi = {10.3390/nu18071026}
}
EUVIMED